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We studied the effects of treatment with olmesartan/
amlodipine and olmesartan/hydrochlorothiazide on
inflammatory and metabolic parameters (including
new-onset diabetes as a secondary endpoint) in non-
diabetic hypertensive patients with metabolic syndrome
(MetS). A total of 120 patients with MetS and stage I
and II hypertension were randomized to olmesartan
20mg/amlodipine 5mg or olmesartan 20mg/hydrochlor-
othiazide 12.5mg. If target systolic blood pressure
(o140mmHg) was not reached, doses were doubled
after 13 weeks; doxazosin 4mg was added after 26
weeks, and doubled after 39 weeks; follow-up ended at
78 weeks. At each visit, blood pressure (BP), fasting
plasma glucose, insulin, adiponectin, tumour necrosis
factor-a, C-reactive protein (CRP), intercellular adhesion
molecule-1, vascular cell adhesion molecule-1, interleu-
kins-1b, -6 and -8, and albuminuria were measured;
BP was similarly reduced in both groups; 80% of
patients reached target BP. Reductions in albuminuria
were also similar (50%). Only olmesartan/amlodipine
reduced the insulin resistance index (24%, Po0.01),
increased plasma adiponectin (16%, Po0.05) and
significantly reduced all of the inflammation markers
studied, except CRP, which showed a similar reduction
in each group. The risk of new-onset diabetes was signi-
ficantly lower with olmesartan/amlodipine (P¼0.02).
Both olmesartan-based combinations were effective,
but the amlodipine combination resulted in metabolic
and anti-inflammatory effects that may have advantages
over the hydrochlorothiazide combination.
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Introduction
The prevalence of metabolic syndrome (MetS) in
patients with essential hypertension is very high,
and has been estimated as being close to 50%.
1
Hypertensive patients with MetS have a much
higher cardiovascular (CV) risk than their counter-
parts without MetS,
2 and also have a particularly
high risk of developing type 2 diabetes mellitus
(T2DM).
3 In addition, the choice of antihypertensive
therapy can have a large impact on the risk of
development of T2DM.
4 Renin–angiotensin system
blockers, that is, angiotensin-converting enzyme
inhibitors and angiotensin receptor blockers (ARBs),
improve insulin sensitivity and reduce the risk of
developing T2DM compared with placebo, whereas
calcium channel blockers (CCBs) have a neutral
effect. Thiazide diuretics and b-blockers decrease
insulin sensitivity and increase the incidence of
T2DM.
4 Therefore, the combination of an ARB and a
CCB might be particularly beneficial in patients
with high metabolic risk.
5
The present European Guidelines for the Manage-
ment of Hypertension acknowledge that most high-
risk hypertensive patients require a combination of
antihypertensive drugs.
6 For patients with MetS, the
recommended combinations are renin–angiotensin
system blockers combined with low-dose thiazide
diuretics or CCBs.
6 In spite of the well-known
effect of antihypertensive treatment on glucose and
lipid metabolism, few studies have been conducted
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7,8
In addition to decreased insulin sensitivity, a low
circulating level of adiponectin is a central feature of
MetS and is strongly associated with the incidence
of T2DM.
9 High circulating levels of inflammatory
markers such as tumour necrosis factor-a (TNF-a),
C-reactive protein (CRP) and interleukins-1b (IL-1b),
IL-6 and IL-8 are also a feature of MetS and increase
the risk of developing T2DM.
10 The adhesion mole-
cules, intercellular adhesion molecule-1 (ICAM-1)
and vascular cell adhesion molecule-1 (VCAM-1)
are also strongly associated with certain features of
MetS,
11 particularly postprandial triglyceride and
insulin levels, and may therefore be implicated in
the development of atherosclerosis and T2DM.
11
Olmesartan is the latest ARB to become available
in clinical practice. A systematic review of the
efficacy of ARBs in studies that used 24-h ambula-
tory blood pressure (BP) monitoring revealed that
olmesartan may achieve greater ambulatory BP
reductions than other ARBs, even though reductions
in office BP were similar.
12 Fixed-dose combinations
of olmesartan with amlodipine and with hydro-
chlorothiazide have recently become available. In
addition to other ancillary actions, amlodipine has
been shown to have a modest insulin-sensitising
effect that is additive to the effect of an ARB.
13,14
The primary objective of this stand-alone study,
OLAS (OLmesartan/Amlodipine vs olmesartan/
hydrochlorothiazide in metabolic Syndrome), was
to investigate the effects of olmesartan/amlodipine
and olmesartan/hydrochlorothiazide combination
therapy on inflammatory (including TNF-a, CRP,
IL-1b, -6 and -8, ICAM-1 and VCAM-1) and meta-
bolic parameters (including insulin sensitivity and
adiponectin), with new-onset T2DM as a secondary
outcome measure, in non-diabetic hypertensive
patients with MetS.
Methods
The patients recruited for this study were all
Europid, aged 25–75 years and had stage I and II
hypertension (systolic BP (SBP) 140–179mmHg)
and MetS, as defined by the International Diabetes
Federation for Europid populations
15 (waist circum-
ference 494cm in men and 480cm in women, and
at least two of the following criteria: triglycerides
41.7mmoll
 1; high-density lipoprotein-cholesterol
o1.03mmoll
 1 in men and o1.29mmoll
 1 in
women; fasting blood glucose 45.6mmoll
 1;B P
4135/80mmHg). Previous antihypertensive ther-
apy, if any, was withdrawn during a washout period
of 3–5 weeks before inclusion.
Patients with diabetes mellitus were excluded
from the study and, in order to unmask hidden
diabetes, a standard oral glucose tolerance test was
performed in patients with fasting blood glucose
45.6mmoll
 1. Patients were also excluded if they
showed evidence of unstable angina, acute coronary
syndrome, myocardial infarction, decompensated
congestive heart failure, stroke or transient ischemic
attack within the previous 6 months, left ventricular
outflow obstruction, liver dysfunction (serum bilir-
ubin 41.5  or plasma aminotransferases 2  the
upper normal limit), renal insufficiency (plasma
creatinine 4133mmoll
 1 in men and 4124mmoll
 1
in women) or overt proteinuria (4300mg per day).
Patients with known hypersensitivity or a history of
severe adverse effects with any ARB, CCB, thiazide
diuretic or a-adrenergic blocker were excluded, as
well as those with any contraindication for olmesartan,
amlodipine, hydrochlorothiazide or doxazosin (based
on the prescribing information for each drug). Pregnant
women, nursing mothers, women of childbearing
potential not using adequate contraceptive methods
and patients with a history of mental illness or
psychiatric disorders were also excluded.
The study was conducted according to standard
good clinical practice guidelines and approved by
the local ethics committee of participating centres.
All participants provided written informed consent
before inclusion.
A parallel-group, prospective, randomized, open-
label, blinded end point design (PROBE) was used,
and all measurements and procedures were per-
formed by personnel blinded to the treatment
allocation.
16 The study design is shown in Figure 1.
After baseline measurements were taken, patients
were randomized to receive olmesartan (20mg)þ
amlodipine (5mg) daily (OA group), or olmesartan
(20mg) þ hydrochlorothiazide (12.5mg) daily (OH
group). After 13±2, 26±2, 39±2 and 78±2 weeks
(approximately 3, 6, 9 and 18 months) all measure-
ments were repeated. Those patients not reaching
the SBP target (o140mmHg) were successively
uptitrated to a double dose of the initial treatment
after 13 weeks, an additional 4mg of doxazosin
(long-acting formulation) after 26 weeks, and 8mg
of doxazosin after week 39. Additional visits were
performed after 52±2a n d6 5 ±2 weeks (12 and
15 months) but only BP, fasting blood glucose,
compliance and tolerance data were obtained.
Figure 1 Design of the OLAS study showing the antihyperten-
sive treatment schedule. The treatment was uptitrated if the target
systolic blood pressure (o140mmHg) had not been reached. A,
amlodipine; D, doxazosin; H: hydrochlorothiazide; O, olmesartan.
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maximum treatment doses but still had SBP
4160mmHg were removed from the study. In all
patients with fasting glycaemia 45.6mmoll
 1 but
o7mmoll
 1 at any visit after the first, a standard
oral glucose tolerance test was performed within the
following 10 days. New-onset T2DM was diagnosed
in patients with fasting glycaemia X7mmoll
 1 or
120min post-load glycaemia 411.1mmoll
 1, in the
absence of clinical signs of type 1 or secondary
diabetes mellitus, according to the current World
Health Organization guidelines.
17
Weight, height, waist circumference, fasting plas-
ma glucose and insulin, lipid profile (that is, total
cholesterol, high-density lipoprotein-cholesterol
and triglycerides), creatinine, sodium, potassium,
bilirubin, aminotransferases, high-sensitivity-CRP,
and urinary albumin and creatinine (in early
morning samples) were measured by standard
clinical procedures. Heart rate and BP were mea-
sured according to current guidelines,
6 using a
validated semi-automatic device (OMRON 705P),
in the morning (between 08:30 and 11:30) after
5min of rest in a sitting position with the back
supported; patients were advised to avoid smoking
and caffeinated drinks 30min before the measure-
ment. The values for BP and heart rate obtained at
each visit were the average of two measurements
separated by at least 2min; a third reading was
obtained if there was a difference of 5mmHg or 5
beats per minute between the two readings.
Plasma TNF-a was measured using a commercial
enzyme-linked immunosorbent assay (ARCUS Bio-
logicals, Modena, Italy); plasma adiponectin, ICAM-
1, VCAM-1 and interleukins-1b, -6 and -8 were also
measured with a commercial enzyme-linked immu-
nosorbent assay (LINCO Research Inc., MO, USA).
The insulin resistance index (IRI) was estimated
by the homeostasis model assessment formula:
18
IRI¼fasting plasma insulin fasting plasma glucose/
135, with insulin in pmoll
 1 (1 mU per l¼
6.00pmoll
 1) and glucose in mmoll
 1. Compliance
was assessed by returned pill counts and tolerance
by questionnaire.
An intention-to-treat analysis was performed in
all patients who received at least one dose of study
medication and had a subsequent efficacy observa-
tion. All analyses were specified a priori, except
where otherwise indicated. All calculations were
performed using the statistical software SPSS 15.0
(SPSS Inc., Chicago, IL, USA) for Microsoft Win-
dows, including logistic regression modelling. The
sample size was calculated with the assumption
(based on a pilot trial) of a 25% difference in the
means between the groups for most of the main
variables (namely IRI, adiponectin, TNF-a, IL-1b,
IL-6, ICAM-1, and VCAM-1), and a 40% variation
coefficient within the groups, yielding 54 patients
per group for a 90% statistical power with a¼0.05.
Assuming a 10% patient loss, a sample size of 60 per
group was required. However, the study could be
underpowered for the secondary objective (new-
onset T2DM), as we did not have enough informa-
tion to calculate an adequate sample size.
The data are presented as mean±s.d., with 95%
confidence intervals for differences as appropriate.
Changes from baseline and between groups in BP,
heart rate and laboratory parameters were evaluated
using a Student’s t-test for paired or unpaired data,
or analysis of variance, as appropriate. Categorical
variables were compared using the w
2 or the Fisher’s
exact tests, as appropriate. The survival analysis
for new-onset T2DM was performed using the
Kaplan–Meier model followed by the log-rank test.
The standard Pearson model was used for correla-
tion analysis. All statistical tests were two-tailed
and a P-value of o0.05 was considered statistically
significant.
Results
Enrolment for this trial began in May 2005, includ-
ing a 6-month, 8-patient pilot trial to check for
feasibility and to confirm the sample size calcula-
tion. A total of 256 patients were screened, of whom
120 were randomized. At baseline, the mean age was
59.3±8.1 years, 55% of patients were female, and
the mean body mass index was 31.2±3.7kgm
 2.
There were 60 patients in each group. The flowchart
of the study is shown in Figure 2.
Of the 120 patients randomized, 31 (25.8%) had
received previous antihypertensive treatment; 17 in
the OA group and 14 in the OH group. None had
received combination treatment and all had a SBP
4140mmHg; three had received a thiazide diuretic,
two a b-blocker, nine a CCB (seven dihydropyridi-
nic, two non-dihydropyridinic), nine an angioten-
sin-converting enzyme inhibitor, seven an ARB and
Figure 2 Flowchart of the OLAS study. Doses are mg per day. A,
amlodipine; D, doxazosin; H, hydrochlorothiazide; O, olmesartan;
OGTT, oral glucose tolerance test; SBP, systolic blood pressure;
T2DM, type 2 diabetes mellitus.
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2-test
showed that these drugs were evenly distributed
between the groups.
BP decreased significantly in each group vs
baseline (Po0.001), but there were no significant
differences in BP control between the groups
(analysis of variance, P¼0.39). Figure 3 shows the
BP values obtained during the study. The final
SBP values were 126.5±9.0 and 129.9±10.9mmHg
for the OA and OH groups, respectively, and
the final diastolic BP values were 84.9±7.3 and
86.3±8.6mmHg. The mean differences between
groups throughout the study were 1.5mmHg for
SBP ( 1.4 to 4.4) and 0.8mmHg for diastolic BP
( 1.8 to 3.6). In the OA group, 53.3% of patients
required doubling of the initial drug doses, and
30.0% required the addition of doxazosin. The
respective figures for the OH group were 53.3 and
31.7%. By week 26, before the addition of doxazo-
sin, 68.3% of patients in the OA group and 66.7%
in the OH group had reached the target BP; at the
end of the study, the respective figures were 81.7
and 78.3%.
The baseline values for all of the quantitative
variables in both groups are presented in Table 1.
There were no significant differences between
groups at baseline. For body mass index, waist
circumference, fasting plasma glucose, sodium,
potassium, creatinine, lipid profile, bilirubin and
aminotransferases, no differences between the treat-
ment groups were found throughout the study; the
final values are presented in Table 2.
The albumin excretion rate decreased signifi-
cantly in both groups (Po0.01), with no between-
group differences. In the OA group, the percentage
reductions were 34.1% at week 26 and 50.0% at
week 78; in the OH group, the reductions were
36.2 and 53.7%, respectively. The 95% confidence
intervals for the differences were, respectively,  7.5
to 11.8% and  5.9 to 13.4%. The IRI and plasma
fasting insulin were significantly reduced in the
OA group (by 24.1 and 25.0%, respectively, both
Po0.01), whereas adiponectin was increased by
16.3% (Po0.01). In the OH group, changes in IRI,
plasma fasting insulin and adiponectin were not
Figure 3 Systolic and diastolic blood pressures during the OLAS
study. Those patients who did not achieve systolic blood pressure
target (o140mmHg) received 4mg of doxazosin at week 26,
which was doubled to 8mg of doxazosin at week 39 if required.
OA, olmesartan/amlodipine; BP, blood pressure; OH, olmesartan/
hydrochlorothiazide.
Table 1 Baseline values for all of the quantitative variables in
both groups
Variable OA group OH group
Age (year) 59.0±7.9 59.5±8.0
Sex (% female) 56.7 53.3
Body mass index (kgm
 2) 31.4±3.8 31.1±4.0
Waist circumference (cm) 106.1±12.9 106.5±11.8
SBP (mmHg) 154.5±10.9 154.9±9.8
DBP (mmHg) 102.5±7.9 101.0±8.3
Fasting glucose (mmoll
 1) 5.52±0.71 5.49±0.66
Plasma Na
+ (mEql
 1) 138±2.7 139±3.2
Plasma K
+ (mEql
 1) 4.6±0.7 4.5±0.8
Plasma creatinine (mmoll
 1) 0.09±0.01 0.09±0.02
Total cholesterol (mmoll
 1) 5.27±1.12 5.25±1.02
HDL-cholesterol (mmoll
 1) 0.99±0.36 1.04±0.39
Triglycerides (mmoll
 1) 1.93±0.83 1.96±0.99
Total bilirubin (mmoll
 1) 12.3±2.6 12.6±4.2
AST (IU per l) 38.3±7.1 37.5±8.4
ALT (IU per l) 35.9±6.2 32.6±7.4
Albumin/creatinine (mgmmol
 1) 3.24±3.04 2.91±3.18
Fasting insulin (pmoll
 1) 83.70±40.26 83.22±33.42
IRI-HOMA (arbitrary units) 3.41±1.1 3.39±0.94
Adiponectin (mgml
 1) 10.71±6.31 10.59±5.44
TNF-a (pgml
 1) 4.25±2.16 4.31±1.97
CRP (mgl
 1) 2.15±0.60 2.2±0.51
IL-1b (pgml
 1) 0.54±0.21 0.53±0.24
IL-6 (pgml
 1) 3.48±2.11 3.46+1.68
IL-8 (pgml
 1) 14.42±6.31 14.77±5.89
ICAM-1 (ngml
 1) 298±58 303±49
VCAM-1 (ngml
 1) 857±321 819±297
Abbreviations: ALT, alanine aminotransferase; AST, aspartate amino-
transferase; BP, blood pressure; CRP, C-reactive protein; DBP, diastolic
blood pressure; HDL, high-density lipoprotein; HOMA, homeostasis
model assessment; ICAM, intercellular adhesion molecule; IL,
interleukin; IRI, insulin resistance index; OA, olmesartan/amlodi-
pine; OH, olmesartan/hydrochlorothiazide; SBP, systolic blood pres-
sure; TNF, tumour necrosis factor; VCAM, vascular cell adhesion
molecule.
There were no significant differences between groups for any of the
variables.
Table 2 Final values (week 78) for the quantitative variables that
did not change significantly in both groups
Variable OA group OH group
Body mass index (kgm
 2) 31.2±3.9 31.6±3.7
Waist circumference (cm) 105.5±11.77 107.1±9.9
Fasting glucose (mmoll
 1) 5.50±0.78 5.57±0.80
Plasma Na
+ (met per l) 138±2.8 138±3.6
Plasma K
+ (mEql
 1) 4.6±0.6 4.4±0.7
Plasma creatinine (mmoll
 1) 0.08±0.02 0.09±0.01
Total cholesterol (mmoll
 1) 5.22±1.23 5.32±0.97
HDL-cholesterol (mmoll
 1) 1.03±0.44 1.01±0.50
Triglycerides (mmoll
 1) 1.83±0.90 2.13±1.12
Total bilirubin (mmoll
 1) 11.8±3.2 12.1±4.3
AST (IU per l) 37.9±6.8 38.0±7.6
ALT (IU per l) 34.1±7.7 33.8±10.1
Abbreviations: ALT, alanine aminotransferase; AST, aspartate amino-
transferase; HDL, High-density lipoprotein; OA, olmesartan/amlodi-
pine; OH, olmesartan/hydrochlorothiazide.
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groups were significant. Figure 4a shows the
percentage changes in albuminuria, fasting insulin,
IRI and adiponectin; the percentage changes in
adiponectin showed an inverse correlation with
the percentage changes in the IRI (Pearson’s R
test¼ 0.54, Po0.001).
Of the inflammation markers studied, only CRP
was significantly reduced in both groups (by 16.7
and 14.1% in the OA and OH groups, respectively,
both Po0.05; 95% confidence intervals for the
difference was  2.1 to 7.2%), with no significant
difference between the two groups. The other
inflammation markers were significantly reduced
in the OA group only (by 16.1% for TNF-a, 18.5%
for IL-1b, 18.1% for IL-6, 12.8% for IL-8, 20.8% for
ICAM-1 and 30.8% for VCAM-1); the between-group
differences were significant for all of these inflam-
mation markers. Figure 4b shows the percentage
changes in all of the inflammation markers studied.
A post hoc analysis was performed within each
group in order to assess the effect of the addition of
doxazosin (after week 26) on the studied variables.
With the exception of a significant reduction in
SBP and diastolic BP (similar for both groups), no
differences could be found between the patients
taking doxazosin and those not receiving doxazosin.
After week 26, the only variables that underwent
significant changes were SBP and diastolic BP
(Figure 3), and new-onset T2DM (Figure 5).
During the study, three patients (5.0%) developed
T2DM in the OA group, compared with 11 (18.3%)
in the OH group (odds ratio 4.24 for OA vs OH;
absolute risk reduction 13.3%). The Kaplan–Meier
survival analysis is plotted in Figure 5. The log-rank
test showed a significant difference between the
groups (P¼0.02). A logistic regression modelling
analysis determined that the predictors of T2DM
development (after adjustement for gender and
baseline values of age, body mass index, waist
circumference and fasting plasma glucose) were:
the IRI (OR 1.27 per 0.5 AU increment, P¼0.013),
OH treatment (OR 3.98, P¼0.023) and low adipo-
nectin (OR 2.26 per 1mgml
 1 decrement, P¼0.043).
The addition of doxazosin showed no correlation
with new-onset T2DM.
The compliance rate was high: 96.1% for the OA
group up to week 26 and 92.7% at the end of the
study; the respective figures were 94.1 and 91.8%
for the OH group. Only one patient withdrew from
the study because of side effects (malleolar oedema,
in the OA group) but minor side effects were
reported by low proportions of patients in the OA
group (oedema (8.3%), headache (6.7%) and flush-
ing or dizziness (1.7%)) and in the OH group
(oedema (3.3%), headache (5.0%) and flushing or
dizziness (5.0%)). Three patients (5.0%) in each
group were withdrawn from the study because of
poor BP control, with SBP 4160mmHg despite full
treatment. There were no differences in the inci-
dence of side effects between the groups (Fisher’s
exact test). None of the patients had hypokalaemia
during the study, and the correlation studies
between potassium and insulin, glucose or IRI were
negative (data not shown).
Figure 4 (a) Percentage change from baseline in urinary
albumin/creatinine quotient, fasting plasma insulin, homeostasis
model assessment index of insulin resistance and plasma
adiponectin. (b) Percentage changes from baseline in inflamma-
tory markers: tumour necrosis factor-a (TNF-a), C-reactive protein
(CRP), interleukins-1b, -6 and -8 (IL-1b, IL-6 and IL-8); inter-
cellular adhesion molecule-1 (ICAM-1) and vascular cell adhe-
sion molecule-1 (VCAM-1). *Po0.05 vs baseline;
wPo0.01 vs
baseline;
zPo0.05 between groups;
yPo0.01 between groups. For
simplicity, only the baseline and final values are shown, but no
significant changes were observed after week 26.
Figure 5 Kaplan–Meier survival analysis for the incidence of
type 2 diabetes mellitus. A, amlodipine; ARR, absolute risk
reduction; H, hydrochlorothiazide; O, olmesartan; OR, odds ratio.
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The findings of this study demonstrate that both
antihypertensive combinations—olmesartan plus am-
lodipine and olmesartan plus hydrochlorothiazide—
are well tolerated and effective in non-diabetic
hypertensive subjects with MetS, and allow achieve-
ment of adequate BP control in the majority of pati-
ents using a simple treatment strategy. Combination
treatment has been shown to increase the efficacy
of treatment and reduce adverse effects.
19 A recent
large meta-analysis has shown that the extra BP
reduction that can be obtained with a combination
of drugs from different classes is approximately five
times greater than the BP reduction produced by
doubling the dose of one drug.
20 The olmesartan/
amlodipine combination was factorially evaluated in
the COACH trial, a large, multicentre, randomized,
double-blind, placebo-controlled study.
21 The olme-
sartan/hydrochlorothiazide combination has also
been extensively studied.
22 Each of these olmesar-
tan-based combinations has been found to be well
tolerated and effective. However, to the best of our
knowledge, neither of the combinations has been
studied specifically in patients with MetS, and data
on their effects in obese hypertensive patients are very
scarce. Most of our patients were obese, as expected
in a group with MetS; moreover, the prevalence of
obesity in our community is among the highest in
Europe.
23 The validity of the MetS concept has been
recently challenged for CV risk prediction,
24 but it
remains a useful predictor of T2DM development.
In the present study, significant reductions in
urinary albumin/creatinine quotient were also
observed in both treatment arms. Microalbuminuria
is highly prevalent in non-diabetic hypertensive
subjects with MetS,
25 and is a well-known marker
of both renal and CV risk.
26 The LIFE trial, in
hypertensive patients with left ventricular hyper-
trophy, showed that reductions in albumin excretion
during treatment translate into a reduction in the
risk of CV events.
27
The OLAS study also shows that there are clear
differences between the two olmesartan-based com-
binations with regard to metabolic and inflamma-
tory markers. It has long been established that
thiazide diuretics impair insulin sensitivity and
increase the incidence of T2DM.
4 This adverse effect
can only partially be explained by hypokalaemia; a
systematic review of the available evidence found
that thiazides are diabetogenic even in the absence
of changes in the plasma potassium level.
28
Thiazide diuretics have been shown to reduce
hard CV endpoints in many large controlled trials,
and are recommended as first-line treatment for
hypertension in the current guidelines.
6,29 However,
most of these trials have been based on chlorthali-
done or indapamide, whereas the currently recom-
mended low doses (up to 25mg per day) of
hydrochlorothiazide have never been shown to
reduce CV morbidity and mortality.
30 Nevertheless,
hydrochlorothiazide is, by far, the most prescribed
thiazide diuretic worldwide, and the one used in
almost all of the available single-pill combinations
containing a diuretic.
The MEchanisms for the DIabetes preventing
effect of CAndesartan (MEDICA) study found that,
compared with candesartan, hydrochlorothiazide
increased insulin resistance in a manner that was
not related to hypokalaemia, but was associated
with fat redistribution, an increase in visceral
adiposity, steatohepatitis and low-grade inflamma-
tion.
31 The Pharmacogenomic Evaluation of Anti-
hypertensive Responses study found that the ad-
verse metabolic effects (including new-onset T2DM)
of hydrochlorothiazide, alone or associated with
atenolol, were more frequent and severe in patients
with abdominal obesity.
32 The Study of Trandolapril/
Verapamil SR And Insulin Resistance (STAR),
showed that in non-diabetic hypertensive patients
with MetS, an angiotensin-converting enzyme in-
hibitor/CCB combination was associated with a
much lower risk of developing diabetes than an
ARB/hydrochlorothiazide combination, despite si-
milar reduction in BP;
7 a correlation with potassium
levels was also excluded. Our results regarding
the development of T2DM are comparable, and
also ruled out thiazide-induced hypokalaemia as
the cause. Moreover, we were able to establish the
predictive role of low adiponectin levels in this
model, even independently of the changes in the
insulin sensitivity index. In fact, low adiponectin is
a powerful independent predictor of T2DM.
9
The clinical relevance of the changes in these
metabolic parameters is unknown, although a higher
incidence of T2DM may not be trivial. The importance
of new-onset T2DM in hypertension trials has been
challenged, as it does not seem to be associated with a
higher risk of mortality or clinical events in the short
term,
33 and for some authors its possible occurrence
should not influence the selection of antihypertensive
drug.
34 Moreover, the STAR Long-Term Extension
Trial showed that it is partially reversible.
35 The
risk associated with new-onset T2DM may become
apparent only in very long-term studies, except in
very high-risk situations. In the VALIANT trial, after
an acute myocardial infarction, patients with pre-
viously known or newly diagnosed diabetes melli-
tus had similarly increased risks of mortality and CV
events, much higher than non-diabetic patients.
36
Recently, the Avoiding Cardiovascular events
through COMbination therapy in Patients LIving
with Systolic Hypertension (ACCOMPLISH) trial
showed a 20% reduction in the risk of CVevents and
mortality with the use of a fixed-dose combination
of benazepril/amlodipine, compared with a fixed-
dose combination of benazepril/hydrochlorothia-
zide, despite similar reduction in BP.
37 These results
point to an, as yet, unknown BP-independent
mechanism, although a reduction in central BP
may also be implied.
38 Although an ARB was
prescribed instead of an angiotensin-converting
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strategies are generally similar, and our results
suggest that the different effects on inflammatory
mediators could contribute to the results shown in
ACCOMPLISH. Blockade of the renin–angiotensin
system has anti-inflammatory actions and, in parti-
cular, olmesartan has been shown to reduce CRP,
TNF-a, IL-6 and monocyte chemotactic protein-1 in
the EUropean Trial on Olmesartan and Pravastatin in
Inflammation and Atherosclerosis (EUTOPIA).
39 Am-
lodipine also has anti-inflammatory properties,
13
whereas hydrochlorothiazide elicits microinflamma-
tion and increases the circulating levels of CRP.
31
The clinical relevance of these findings is, however,
not yet established.
The PROBE design may introduce investigator
bias but has been validated in many hypertension
trials to date, and reflects usual clinical practice
more closely than a randomized controlled design.
40
Another limitation of the present study is a small,
not significant but consistent difference in blood
pressure (1.5/0.8mmHg lower in the OA group).
However, a post hoc analysis did not find a
significant correlation between this difference and
the observed changes in metabolic and inflamma-
tion parameters.
In conclusion, both the olmesartan/amlodipine
and olmesartan/hydrochlorothiazide combinations
were effective and well tolerated in this study,
but the effects on metabolic and inflammatory
markers and on new-onset T2DM were possibly more
favourable for the combination containing the CCB.
The impressive results of the ACCOMPLISH trial on
hard CVendpoints have not been explained, but our
study may be hypothesis-generating and stimulate
further research that may eventually elucidate the
BP-independent protection afforded by the renin–
angiotensin system blocker/CCB combination.
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